The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVEC.L Share News (VEC)

  • There is currently no data for VEC

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-When M&A is Made in Britain

Mon, 02nd Aug 2021 14:24

* U.S. equity index futures suggest modest opening gains

* Euro STOXX 600 index up ~0.5%

* Dollar, gold, crude, bitcoin all dip

* U.S. 10-Year Treasury yield ~1.21%

Aug 2 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

WHEN M&A IS MADE IN BRITAIN (0914 EDT/1314 GMT)

The U.S. takeover of engineer Meggitt is just the
latest in a series of M&A moves targeting Britain recently.

Morrison, Ultra, Vectura and Sanne
are other examples but beyond the market moving
headlines hard data also backs the view that Britain has proved
a particularly fertile ground for M&A this year.

Cross-border M&A with a UK target has increased by 340% to
$132.5 billion year to date, the latest Refintiv data to
end-July show. That's about nine times the 39% growth seen in
Europe and well above growth in the Americas (+200%) and Asia
(+182%).

"Now after all the fear mongering post Brexit has been
proven wrong UK companies are certainly of interest," says a
London-based trader. "Many companies and also Private Equity too
are looking to diversify in regard to location and are often
underinvested in the UK".

And beyond the volumes, investors in UK Plc appear to like
it, whereas it is becoming harder for acquirers to get a bargain
even though British companies are not necessarily overvalued at
this stage.

Meggitt shares shot up more than 60% this morning and that
in turn has helped the domestically focused mid-cap and FTSE 250
index race to a new record high.

"I am quite impressed by the massive premium which is being
paid for Meggitt," says the trader.

And AJ Bell investment director Russ Mould notes: "Private
equity firms have a reputation for trying to get a bargain, but
their tactics have been fully exposed this year and it now seems
rare for the first offer to be the winning one."

For more reading: BREAKINGVIEWS-UK plc’s latest sale is far
from on the cheap

(Danilo Masoni)

*****

S&P 500: FROM BULLISH FODDER TO BEARISH DUST? (0900 EDT/1300
GMT)

Amid on-going Federal Reserve support, the economic
re-opening, S&P 500 Q2 2021 year-over-year earnings
growth running at nearly 90%, and now a $1 trillion
infrastructure bill unveiled by U.S. Senators raising hopes of
more fiscal stimulus, there certainly is plenty of fodder for
bulls to be excited about.

So far, the S&P 500 index's record closing high was
on Monday July 26. Since then the benchmark index has
essentially chopped sideways, ending Friday just around 0.6%
below that high.

With this, however, a contrarian measure of sentiment, based
on the CBOE equity put/call (P/C) ratio, is exhibiting a pattern
that has preceded periods of market instability:

With the SPX's all-time high close, the 5-day moving average
of the P/C ratio fell to 41.6%. This put it just slightly above
its relatively recent, multi-decade lows. This measure's
depressed readings can flag an excessively bullish, or
especially complacent market, vulnerable to a reversal.

Indeed, what may be a more robust bearish signal is when the
moving average puts in a higher-low, against a higher SPX high.
This pattern developed ahead of declines of varying degree over
the last two years or so, including the severe sell-offs in late
2018 and early 2020.

In the wake of its 37.6% December 7 trough, which was its
lowest reading since around the time of the Y2K tech-bubble
peak, the measure has put in higher lows at 37.8% on January 14,
38.4% on February 11, and 39.6% on June 14. It has since vaulted
to 54.2%, despite just a modest drop in the index.

Thus, this measure may be signaling cracks are forming in
what has been solidly bullish sentiment. If so, instability may
be just around the corner.

(Terence Gabriel)

*****

FOR MONDAY'S LIVE MARKETS' POSTS PRIOR TO 0900 EDT/1300 GMT
- CLICK HERE:

(Terence Gabriel is a Reuters market analyst. The views
expressed are his own)

More News
18 Dec 2020 08:12

Hikma rallies as it launches generic version of Glaxo asthma treatment

(Sharecast News) - Hikma Pharmaceuticals shares rallied after the company said it had received approval from the US Food and Drug Administration and launched its generic version of GlaxoSmithKline's asthma treatment, Advair Diskus.

Read more
17 Dec 2020 18:10

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Hikma Pharmaceuticals Gets US FDA Approval For Generic Advair Diskus

Read more
4 Dec 2020 13:05

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

IN BRIEF: Tissue Regenix Adds Former Vectura COO To Board

Read more
30 Nov 2020 09:53

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Vectura Inks Agreement To Support Kinaset Therapeutics For Asthma Drug

Read more
30 Nov 2020 08:06

Vectura signs asthma treatment deal with Kinaset

(Sharecast News) - Vectura has signed a global licence and development deal with Kinaset Therapeutics of the US for the development and commercialisation of the VR588 pan-JAK asthma treatment.

Read more
20 Nov 2020 08:34

Court denies GSK appeal in Vectura intellectual property dispute

(Sharecast News) - Inhalation-focussed contract design and manufacture organisation Vectura Group announced on Friday that the United States Court of Appeals for the Federal Circuit has denied GlaxoSmithKline's (GSK) motions for judgment as a matter of law, a new trial on infringement, and for a new trial on damages in litigation concerning Vectura's US patent 8303991.

Read more
19 Nov 2020 20:25

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

IN BRIEF: Vectura Notes US Court Denying GSK's Motions For New Trials

Read more
28 Sep 2020 15:53

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

UK EXECUTIVE CHANGE SUMMARY: Tracsis Appoints New Finance Chief

Read more
22 Sep 2020 19:34

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

IN BRIEF: Vectura Notes Hikma's Advair US Regulatory Setback

Read more
15 Sep 2020 17:22

Vectura Revenue Slips But Swings To First Half Profit

Vectura Revenue Slips But Swings To First Half Profit

Read more
14 Sep 2020 17:21

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

UK TRADING UPDATE SUMMARY: Henry Boot Unit In Voluntary Liquidation

Read more
2 Sep 2020 19:36

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

TOP NEWS: ITV Bumped From FTSE 100 For B&M European Value Retail

Read more
7 Jul 2020 16:35

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

UK TRADING UPDATE SUMMARY: Retailer Sosandar In Quarterly Revenue Jump

Read more
9 Jun 2020 12:04

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

DIRECTOR DEALINGS: Vectura Group Non-Exec Matthews Buys First Shares

Read more
8 Jun 2020 15:00

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Vectura Inks Deal With Aerami To Develop Inhaled Imatinib

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.